<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757534</url>
  </required_header>
  <id_info>
    <org_study_id>201504713</org_study_id>
    <nct_id>NCT02757534</nct_id>
  </id_info>
  <brief_title>Domperidone for Chronic Nausea and Vomiting</brief_title>
  <official_title>Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yehudith Assouline-Dayan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide oral domperidone to patients with gastroparesis,&#xD;
      between the ages of 18 and 60 years of age, who have failed standard treatment. Standard&#xD;
      therapy at the University of Iowa is eating blended foods, liquid diet, Eryped syrup (125 mg&#xD;
      TID) 30 minutes before meals, or reglan (20 mg BID).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a compassionate use research study for a non-FDA approved drug. We are inviting&#xD;
      patients to participate in this research study because they have nausea and vomiting related&#xD;
      to gastroparesis and have failed standard therapy. The purpose of this research study is to&#xD;
      prescribe patients with domperidone. Domperidone is considered investigational, which means&#xD;
      that it has not been approved by the FDA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Gastroparesis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female&#xD;
&#xD;
          2. Age 18 - 60&#xD;
&#xD;
          3. Symptoms or manifestation secondary to gastroparesis such as vomiting, nausea, the&#xD;
             feeling you are full after you start eating, bloating and abdominal pain.&#xD;
&#xD;
          4. Subjects must have a comprehensive evaluation to eliminate other causes of their&#xD;
             symptoms which includes gastric emptying scintigraphy, esophagogastroduodenoscopy&#xD;
             (EGD), and the patient's subjective symptoms.&#xD;
&#xD;
          5. Subject has signed informed consent for the administration of domperidone that informs&#xD;
             the patient of potential adverse events including:&#xD;
&#xD;
               -  increased prolactin levels&#xD;
&#xD;
               -  extrapyramidal side effects&#xD;
&#xD;
               -  breast changes&#xD;
&#xD;
               -  cardiac arrhythmias including QT prolongation and death&#xD;
&#xD;
          6. Female subjects must be:&#xD;
&#xD;
               -  surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal&#xD;
                  ligation)&#xD;
&#xD;
               -  if sexual active, practicing an effective method of birth control such as&#xD;
                  hormonal prescription oral contraceptives, progesterone implants or injections,&#xD;
                  contraceptive patch, intrauterine device, or maintenance of a monogamous&#xD;
                  relationship with a male partner who has been surgically sterilized by vasectomy.&#xD;
                  A double barrier method such as condoms, diaphragms, or cervical caps with&#xD;
                  spermicidal foam, cream, or gel may be used as a method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of, or current, arrhythmias including ventricular tachycardia, ventricular&#xD;
             fibrillation, atrial fibrilation and Torsade des Pointes, subjects with minor forms of&#xD;
             ectopy (PACs) are not necessarily excluded&#xD;
&#xD;
          2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged&#xD;
             corrected QT interval (QTc) (QTc&gt;450 milliseconds for males, QTc&gt;470 milliseconds for&#xD;
             females)&#xD;
&#xD;
          3. Clinically significant electrolyte disorders&#xD;
&#xD;
          4. Hepatic dysfunction&#xD;
&#xD;
          5. Renal insufficiency&#xD;
&#xD;
          6. Gastrointestinal hemorrhage or obstruction&#xD;
&#xD;
          7. Presence of a prolactinoma (prolactin-releasing pituitary tumor)&#xD;
&#xD;
          8. Pregnant or breast feeding female&#xD;
&#xD;
          9. Known allergy to domperidone&#xD;
&#xD;
        The following medications are prohibited during the study:&#xD;
&#xD;
          1. Antidepressants: doxepin (Adapin®, Sinequan®, Zonalon®), clomipramine (Anafranil®),&#xD;
             amoxapine (Asendin®), trazodone (Desyrel®), venlafaxine (Effexor®), nefazodone&#xD;
             (Serzone®), fluvoxamine (Luvox®), paroxetine (Paxil®), fluoxetine (Prozac®, Sarafem®),&#xD;
             nefazodone (Serzone®), sertraline (Zoloft®), amitriptyline (Elavil®, Endep®, Etrafon®,&#xD;
             Limbitrol®, Triavil®), maprotiline (Ludiomil®), desipramine (Norpramin®),&#xD;
             nortriptyline (Pamelor®), trimipramine (Surmontil®), imipramine (Tofranil®),&#xD;
             protriptyline (Vivactil®),&#xD;
&#xD;
          2. Anti-psychotics: haloperidol (Haldol®), chlorpromazine (Thorazine®, Ormazine®),&#xD;
             chlorpromazine pimozide (Orap®), sertindole (Serlect®), quetiapine (Seroquel®),&#xD;
             mesoridazine (Serentil®), perphenazine (Triavil®), fluphenazine (Apo-Fluphenazine®,&#xD;
             Modecate Concentrate®, Moditen®, Permitil®, phenazine methosulfate-Fluphenazine®,&#xD;
             Prolixin®, Rho-Fluphenazine®), promazine (Sparine®), trifluoperazine (Stelazine®)&#xD;
&#xD;
          3. Anti-Emetics: prochlorperazine (Compazine®), thioridazine (Mellaril®), promethazine&#xD;
             (Phenergan®), mesoridazine (Serentil®), thiethylperazine, (Torecan®), perphenazine&#xD;
             (Trilafon®), dolasetron (Anzemet®), dronabinol (Marinol®), droperidol (Inapsine®)&#xD;
&#xD;
          4. Anti-infective agents: erythromycin (such as E.E.S.®, E-Mycin®, Ilotycin® ,&#xD;
             Pediazole®, Akne-mycin®), clarithromycin (Biaxin®), troleandomycin (TAO®), norfloxacin&#xD;
             (Ciproxin®, Noroxin®), quinine sulfate, quinupristin and dalfopristin (Synercid®),&#xD;
             pentamidine (Nebupent®, Pentacarinat®, Pentam®), sparfloxacin (Zagam®), grepafloxacin&#xD;
             (Raxar®), azithromycin (Zithromax®), ofloxacin (Floxin®). Levofloxacin (Levaquin®)&#xD;
&#xD;
          5. Anti-Fungal Agents: fluconazole (Diflucan®), itraconazole (Sporanox®), ketoconazole&#xD;
             (Nizoral®), miconazole (Micatin®, Monistat®), terconazole (Terazol®), tioconazole&#xD;
             (Vagistat®), butoconazole (Femstat 3®)&#xD;
&#xD;
          6. Antivirals: foscarnet (Foscavir®)&#xD;
&#xD;
          7. Protease Inhibitors: indinavir (Crixivan®), amprenavir (Agenerase®), ritonavir&#xD;
             (Norvir®), nelfinavir (Viracept®), saquinavir (Invirase®, Fortovase®),&#xD;
&#xD;
          8. Anti-Hypertensives: nicardipine (Cardene®), isradipine (Dynacirc®), moexipril/&#xD;
             hydrochlorothiazide (HCTZ) (Uniretic®)&#xD;
&#xD;
          9. Calcium Channel Blockers: verapamil (Calan®), diltiazem (Cardizem®),&#xD;
             diltiazem/enalapril (Teczem®), verapamil/trandolapril (Tarka®), tocainide (Tonocard®),&#xD;
             bepridil (Vascor®)&#xD;
&#xD;
         10. Anti-Arrhythmics: disopyramide (Norpace®, Norpace Controlled Release ®), quinidine&#xD;
             (such as Quinidex®, Cardioquin®, Quinaglute®, Duraquin®), procainamide (Procanbid® ,&#xD;
             Procan®, Pronestyl®,), flecainide (Tambocor®), sotalol (Betapace®), bretylium&#xD;
             (Bretylol®), amiodarone (Cordarone®), ibutilide (Corvert®), moricizine (Ethmozine®)&#xD;
&#xD;
         11. Diuretics: bumetanide (Bumex®), furosemide (Lasix®), torsemide (Demadex®), ethacrynic&#xD;
             Acid (Edecrin®), chlorothiazide (Diuril®), Indapamide (Lozol®)&#xD;
&#xD;
         12. Antilipemics: probucol (Lorelco®), Bepridil (Vascor®), mibefradil (Posicor®),&#xD;
&#xD;
         13. Hematological Agents: cilostazol (Pletal®)&#xD;
&#xD;
         14. Respiratory Agents: zafirlukast (Accolate®), salmeterol (Serevent®)&#xD;
&#xD;
         15. Gastrointestinal Agents: cimetidine (Tagamet®), cisapride (Propulsid®)&#xD;
&#xD;
         16. Antidiarrheal: octreotide (Sandostatin®)&#xD;
&#xD;
         17. Antihistamines: azelastine (Astelin®), clemastine (Tavist®)&#xD;
&#xD;
         18. Migraine treatment: naratriptan (Amerge®), sumatriptan (Imitrex®), zolmitriptan&#xD;
             (Zomig®)&#xD;
&#xD;
         19. Antimalarial: halofantrine&#xD;
&#xD;
         20. Muscle relaxants: tizanidine (Zanaflex®)&#xD;
&#xD;
         21. Narcotic Dependence: levomethadyl (Orlaam®)&#xD;
&#xD;
         22. Miscellaneous: tamoxifen (Nolvadex®), warfarin (Coumadin®), phenytoin (Dilantin®),&#xD;
             ziprasidone (Geodon®), risperidone (Risperdal®), formoterol fumarate (Foradil&#xD;
             Aerolizer®), sildenafil (Viagra®)&#xD;
&#xD;
         23. Drugs that prolong the QT Interval: albuterol, alfuzosin, amantadine, amisulpride,&#xD;
             amphetamine, arsenic trioxide, astemizole, atazanavir, atomoxetine, chloral hydrate,&#xD;
             chloroquine, ciprofloxacin, citalopram, clozapine, cocaine, dexmethylphenidate,&#xD;
             diphenhydramine, dobutamine, dofetilide, dopamine, dronedarone, ephedrine,&#xD;
             epinephrine, eribulin, escitalopram, famotidine, felbamate, fenfluramine, fingolimod,&#xD;
             fosphenytoin, galantamine, gatifloxacin, gemifloxacin, granisetron, iloperidone,&#xD;
             isoproterenol, lapatinib, levalbuterol, lisdexamfetamine, lithium, metaproterenol,&#xD;
             methadone, methylphenidate, midodrine, moxifloxacin, nilotinib, norepinephrine,&#xD;
             ondansetron, oxytocin, paliperidone, perflutren lipid microspheres, phentermine,&#xD;
             phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine,&#xD;
             ritodrine, roxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus,&#xD;
             telithromycin, terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib,&#xD;
             vardenafil, voriconazole.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehudith Assouline-Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Yehudith Assouline-Dayan</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

